In the last trading session, 1.01 million ProQR Therapeutics N.V (NASDAQ:PRQR) shares changed hands as the company’s beta touched 0.40. With the company’s per share price at $3.78 changed hands at -$0.27 or -6.67% during last session, the market valuation stood at $308.75M. PRQR’s last price was a discount, traded about -22.22% off its 52-week high of $4.62. The share price had its 52-week low at $1.11, which suggests the last value was 70.63% up since then. When we look at ProQR Therapeutics N.V’s average trading volume, we note the 10-day average is 6.35 million shares, with the 3-month average coming to 1.10 million.
Analysts gave the ProQR Therapeutics N.V (PRQR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended PRQR as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. ProQR Therapeutics N.V’s EPS for the current quarter is expected to be -0.11.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ProQR Therapeutics N.V (NASDAQ:PRQR) trade information
Instantly PRQR was in red as seen at the end of in last trading. With action 108.84%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 90.91%, with the 5-day performance at 108.84% in the green. However, in the 30-day time frame, ProQR Therapeutics N.V (NASDAQ:PRQR) is 125.00% up. Looking at the short shares, we see there were 0.15 million shares sold at short interest cover period of 1.39 days.
The consensus price target for the stock as assigned by Wall Street analysts is 3.75, meaning bulls need a downside of -0.8% from its current market value. According to analyst projections, PRQR’s forecast low is 2 with 5 as the target high. To hit the forecast high, the stock’s price needs a -32.28% plunge from its current level, while the stock would need to tank 47.09% for it to hit the projected low.
ProQR Therapeutics N.V (PRQR) estimates and forecasts
Data shows that the ProQR Therapeutics N.V share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 87.13% over the past 6 months, a 18.42% in annual growth rate that is considerably higher than the industry average of 17.20%. Year-over-year growth is forecast to reach 175.50% up from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 12.04M. 4 analysts are of the opinion that ProQR Therapeutics N.V’s revenue for the current quarter will be 5.53M. The company’s revenue for the corresponding quarters a year ago was 1.49M and 6.75M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 709.10%. The estimates for the next quarter sales put growth at -18.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 21.74%. The 2024 estimates are for ProQR Therapeutics N.V earnings to increase by 2.98%.
PRQR Dividends
ProQR Therapeutics N.V is expected to release its next quarterly earnings report in November.
ADAGE CAPITAL PARTNERS GP, L.L.C. holds the second largest percentage of outstanding shares, with 4.4446% or 3.63 million shares worth $6.02 million as of 2024-06-30.
